Last reviewed · How we verify
Duloxetine hydrochloride enteric-coated capsules
Duloxetine hydrochloride enteric-coated capsules is a Serotonin-norepinephrine reuptake inhibitor Small molecule drug developed by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.. It is currently in Phase 2 development for Major depressive disorder, Generalized anxiety disorder, Diabetic peripheral neuropathic pain. Also known as: Duloxetine.
Selective serotonin and norepinephrine reuptake inhibitor
Selective serotonin and norepinephrine reuptake inhibitor Used for Major depressive disorder, Generalized anxiety disorder, Diabetic peripheral neuropathic pain.
At a glance
| Generic name | Duloxetine hydrochloride enteric-coated capsules |
|---|---|
| Also known as | Duloxetine |
| Sponsor | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
| Drug class | Serotonin-norepinephrine reuptake inhibitor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
Duloxetine hydrochloride acts by inhibiting the reuptake of serotonin and norepinephrine, increasing their concentrations in the synaptic cleft and enhancing neurotransmission.
Approved indications
- Major depressive disorder
- Generalized anxiety disorder
- Diabetic peripheral neuropathic pain
Common side effects
- Nausea
- Dry mouth
- Headache
Key clinical trials
- A Phase II Study to Evaluate NH102 for Depression (PHASE2)
- A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression (PHASE2)
- Study of Desvenlafaxine in Treating Major Depressive Disorder. (PHASE3)
- Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression (PHASE2)
- Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Feeding Conditions (PHASE1)
- Bioavailability of Duloxetine 60 mg With Regards to Reference Product in Fasting Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Duloxetine hydrochloride enteric-coated capsules CI brief — competitive landscape report
- Duloxetine hydrochloride enteric-coated capsules updates RSS · CI watch RSS
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd. portfolio CI
Frequently asked questions about Duloxetine hydrochloride enteric-coated capsules
What is Duloxetine hydrochloride enteric-coated capsules?
How does Duloxetine hydrochloride enteric-coated capsules work?
What is Duloxetine hydrochloride enteric-coated capsules used for?
Who makes Duloxetine hydrochloride enteric-coated capsules?
Is Duloxetine hydrochloride enteric-coated capsules also known as anything else?
What drug class is Duloxetine hydrochloride enteric-coated capsules in?
What development phase is Duloxetine hydrochloride enteric-coated capsules in?
What are the side effects of Duloxetine hydrochloride enteric-coated capsules?
Related
- Drug class: All Serotonin-norepinephrine reuptake inhibitor drugs
- Manufacturer: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Major depressive disorder
- Indication: Drugs for Generalized anxiety disorder
- Indication: Drugs for Diabetic peripheral neuropathic pain
- Also known as: Duloxetine
- Compare: Duloxetine hydrochloride enteric-coated capsules vs similar drugs
- Pricing: Duloxetine hydrochloride enteric-coated capsules cost, discount & access